The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
April 22nd 2024
Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Nail Involvement May Reduce Efficacy of Ustekinumab For Psoriasis
December 9th 2021Nail involvement was shown to reduce the effectiveness of ustekinumab in the treatment of moderate to severe psoriasis, whereas secukinumab exhibited overall higher efficacy than ustekinumab and similar response rates regardless of nail involvement.
Read More
Patients With Psoriatic Disease May Have Greater Risk of VTE, PVD
December 6th 2021Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.
Read More
Brodalumab Improves Skin Clearance, QOL vs Ustekinumab in Comorbid Psoriasis, PsA
December 2nd 2021Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).
Read More
TNF Inhibitors Show Real-world Efficacy on QOL of Patients With Nail Psoriasis, PsA
November 29th 2021Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.
Read More
Assessing Risk Factors for PsA Development in Patients With Psoriasis
November 26th 2021Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.
Read More
Greater Work Impairment, Comorbidity Burden Linked With Concomitant Psoriasis, PsA
November 20th 2021Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.
Read More
Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA
November 17th 2021Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.
Read More
Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis
November 12th 2021Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.
Read More
Ixekizumab Linked With Improved Outcomes vs Adalimumab in PsA With Concomitant Psoriasis
November 3rd 2021A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.
Read More
Economic Burden of Joint Disease in Psoriasis: US Claims Analysis
This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.
Read More
Biologic Treatment, Smoking May Increase Psoriasis Risk in Patients With IBD
October 29th 2021Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.
Read More
Ixekizumab Improves Retention vs Secukinumab in Patients With Psoriasis
October 20th 2021Biologic-experienced patients with psoriasis exhibited significantly improved treatment adherence and lower discontinuation, nonpersistence, and switching rates over 18 months when prescribed ixekizumab vs secukinumab.
Read More
Evaluating Treatment Goals, Preferences in Parents and Young Patients With Psoriasis
October 15th 2021Pediatric populations, young adults, and parents all identified differing goals and preferences of treatment for psoriasis, with the most important treatment goals overall cited as lesion prevention and reduction.
Read More
Brodalumab May Enhance Skin Clearance, QOL vs Ustekinumab for Psoriasis
October 6th 2021Patients with moderate to severe psoriasis were shown to achieve and maintain higher levels of complete skin clearance and quality of life when treated with brodalumab vs ustekinumab, regardless of the presence of lifestyle risk factors.
Read More
High Rate of Secukinumab Retention Shown Long Term in Patients With Psoriasis
October 1st 2021Secukinumab was associated with a high rate of short- and long-term drug survival in the treatment of patients with psoriasis, with factors such as obesity and prior biologic use linked to discontinuation of use.
Read More
Body Surface Area May Predict Risk of Psoriatic Arthritis in Patients With Psoriasis
September 22nd 2021Greater body surface area was shown to correlate with an increased risk of psoriatic arthritis development in patients with psoriasis, with obesity and depression also identified as risk factors.
Read More
Guselkumab Associated With Improved HRQOL, Skin Manifestations in Patients With Psoriasis
September 18th 2021Treatment of guselkumab was found to be safe and effective in improving health-related quality-of-life (HRQOL) and skin manifestations of patients with moderate to severe psoriasis in a real-world setting.
Read More
High OOP Costs for Treatment of Psoriatic Disease Found in Medicare Beneficiaries
September 15th 2021Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.
Read More
Alpha-Glucosidase Inhibitor Use in Type 2 Diabetes Linked With Increased Psoriatic Disease Risk
September 11th 2021Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.
Read More
Phase 2 Study Finds Tildrakizumab Effective for PsA Manifestations
September 9th 2021Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.
Read More